Clinical trial NCT02310321: A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
Official title: A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Acute Myeloid Leukemia
FLT3-mutated Acute Myeloid Leukemia
Keywords: Acute Myeloid Leukemia
Cytarabine
Idarubicin
ASP2215
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2014-12-08
Enrollment: 97
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of phase 1 part in this study was to determine the maximum tolerated dose (MTD) and/or recommended expansion dose (RED) of ASP2215 concomitant with cytarabine/idarubicin as induction chemotherapy based on the status of the onset of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part also evaluated safety and tolerability and characterized the pharmacokinetic (PK) parameters of ASP2215 concomitant with induction and consolidation chemotherapy as well as evaluated the PK parameters of cytarabine concomitant with ASP2215.

The purpose of phase 2 part was to evaluate efficacy of ASP2215 in combination with induction therapy. Phase 2 cohort also evaluated safety and characterized the PK parameters of ASP2215 in combination with induction and consolidation therapy followed by maintenance therapy in newly diagnosed FLT3-mutated AML subjects.

Detailed description: This study was composed of Phase 1 part (the dose-evaluation part and the expansion part) and Phase 2 part.

In the dose-evaluation part of Phase 1 part, at least 3 subjects received ASP2215 at each dose (low, middle, and high) for determination of MTD and/or RED. Treatment of AML in Phase 1 part was composed of 3 periods of therapy: remission induction, consolidation, and maintenance. The decision of whether or not to proceed to the next dose was made based on the occurrence of DLT during Cycle 1 of the induction period.

In the expansion part of Phase 1 part, a maximum of 3 subjects received ASP2215 at RED that had been recommended in the dose-evaluation part and the safety was assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.

In Phase 2 part, Subjects received ASP2215 at the recommended dose established in Phase 1 part. The target population was limited to newly diagnosed FLT3-mutated AML.

Eligibility criteria: Inclusion Criteria:

\[Phase 1 part\]

* Subject is defined as having previously untreated de novo AML according to the World Health Organization (WHO) criteria (2008) within 28 days prior to study enrollment.
* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
* Subject must meet all of the following criteria in the laboratory test at screening:

  * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of ≤ 2.5 × institutional upper limit of normal (ULN)
  * Total serum bilirubin level of ≤ 1.5 × institutional ULN
  * Serum creatinine level of ≤ 1.5 × institutional ULN or an estimated glomerular filtration rate (eGFR) of \> 50 mL/min
* Subject is suitable for oral administration of ASP2215.
* Female subject falls under the following:

  * Of non-childbearing potential:
  * ・Post-menopausal (defined as at least 1 year with no menses without a medical reason such as drug administration) at screening, or
  * ・Documented surgically sterile or status post-hysterectomy (at least 1 month prior to screening)
  * Of childbearing potential:
  * ・Has a negative result for the pregnancy test at screening, and
  * ・Agrees to use an appropriate contraception starting at screening and throughout the study period and for 60 days after the final study drug administration
* Female subject agrees not to breastfeed starting at screening and throughout the study period and for 60 days after the final study drug administration.
* Female subject agrees not to donate ova starting at screening and throughout the study period and for 60 days after the final study drug administration.
* Male subject and his female spouse/partner who is of childbearing potential agrees to use an appropriate contraception starting at screening and throughout the study period and for 120 days after the final study drug administration.
* Male subject agrees not to donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
* Subject agrees not to participate in another interventional study while on study treatment.
* Subject can be admitted during the induction period.

\[Phase 2 part\]

* Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to World Health Organization (WHO) classification (2017) documented within 28 days prior to enrollment.
* Subject is positive for FLT3-ITD and/or TKD mutation in bone marrow or whole blood as determined by the central lab. Registration by the local lab result is not acceptable.
* Subject has an ECOG performance status (PS) 0 to 1. Subject who has an ECOG PS 2 is eligible only if the primary disease related symptoms such as pneumonia and febrile neutropenia are the cause of PS score.
* Subject is suitable for oral administration of ASP2215.
* Female subject is not pregnant and at least 1 of the following conditions apply:

  * Not a woman of childbearing potential (WOCBP)
  * WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.
* Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days after the final study drug administration.
* Female subject must not donate ova starting at screening and throughout the study period, and for 180 days after the final study drug administration.
* Male subject and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at screening and continue throughout the study period and for 120 days after the final study drug administration.
* Male subject must not donate sperm starting at screening and throughout the study period and for 120 days after the final study drug administration.
* Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 120 days after the final study treatment administration.
* Subject agrees not to participate in another interventional study while on treatment.
* Subject must meet the following criteria as indicated on the clinical laboratory tests:

  * Serum creatinine ≤ 1.5 × institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) \> 50 mL/min/1.73m\^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
  * Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
  * Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 x ULN. If liver abnormality by the primary disease is suspected, subject may be pre-registered to initiate the chemotherapy. Prior to registration, AST/ALT values must meet the criteria to continue the study.
  * Serum magnesium ≥ institutional lower limit of normal (LLN). Subject may pre-register without magnesium value, but subject must meet the criteria prior to the full registration on Day 8.
  * Serum potassium ≥ institutional lower limit of normal (LLN).

Exclusion Criteria:

\[Phase 1 part\]

* Subject was diagnosed with acute promyelocytic leukemia (APL).
* Subject has breakpoint cluster region-abelson (BCR-ABL)-positive leukemia (chronic myelogenous leukemia in blast crisis).
* Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS).
* Subject has received prior AML treatment except for the following:

  * Urgent leukapheresis
  * Hydroxyurea administration for emergency treatment of hyperleukocytosis (≤ 7 days)
  * Administration of retinoic acid before the diagnosis to exclude APL (≤ 7 days)
  * Supportive care using growth factors or cytokines
  * Steroid administration to treat hypersensitivity or blood transfusion reactions
* Subject has clinically active central nervous system leukemia.
* Subject has disseminated intravascular coagulation (DIC).
* Subject has had major surgery within 28 days prior to the first study drug administration.
* Subject has had radiation therapy within 28 days prior to the first study drug administration.
* Subject has congestive heart failure of New York Heart Association (NYHA) class 3 or 4, or subject with a past history of congestive heart failure of NYHA class 3 or 4 and in whom echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of \< 45%.
* Subject has cardiac impairment or a clinically significant cardiac disease, including any one of the following:

  * Complete left bundle branch block
  * Obligate use of a cardiac pacemaker
  * Long QT syndrome at Screening
  * Prolongation of the QTc interval (\> 450 ms) on electrocardiogram (ECG) at screening
  * Right bundle branch block + left anterior hemiblock (bifascicular block)
  * Angina pectoris within 3 months prior to study drug administration
  * Acute myocardial infarction within 3 months prior to study drug administration
* Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
* Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
* Subject requires treatment with concomitant drugs that target serotonin 5HT1 or 5HT2B receptors or sigma receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
* Subject has an active uncontrollable infection.
* Subject is known to have human immunodeficiency virus (HIV) infection.
* Subject has active hepatitis B or C or other active hepatic disorders.
* Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.
* Potassium and magnesium levels of below institutional lower limit of normal in the laboratory test at screening.

\[Phase 2 part\]

* Subject was diagnosed with acute promyelocytic leukemia (APL).
* Subject has known BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
* Subject has therapy-related AML.
* Subject has active malignant tumors other than AML.
* Subject has received previous therapy for AML, with the exception of the following:

  * Emergency leukapheresis
  * Emergency treatment for hyperleukocytosis with hydroxyurea for ≤ 10 days
  * Preemptive treatment with retinoic acid prior to exclusion of APL ≤ 7 days
  * Growth factor or cytokine support
  * Steroids for the treatment of hypersensitivity or transfusion reactions.
* Subject has QTcF interval \> 450 ms (average of triplicate determinations based on central reading).
* Subject with long QT syndrome.
* Subject has clinically active central nervous system leukemia.
* Subject has had major surgery within 4 weeks prior to the first study dose.
* Subject has radiation therapy within 4 weeks prior to the first study dose.
* Subject has immediate life-threatening, severe complications of leukemia such as severe uncontrolled bleeding and/or severe disseminated intravascular coagulation
* Subject is known to have human immunodeficiency virus infection.
* Subject has active hepatitis B or C.
* Subject has an uncontrolled infection. An infection controlled with an approved or closely monitored antibiotic/antiviral/antifungal treatment is allowed.
* Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure of NYHA class 3 or 4 and echocardiogram (ECHO) or Multiple Gate Acquisition (MUGA) scan performed within 3 months prior to screening or at screening showed a left ventricular ejection fraction (LVEF) of \< 45%.
* Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
* Subject requires treatment with concomitant drugs that target serotonin 5HT2B receptors or sigma nonspecific receptors, with the exception of drugs that are considered absolutely essential for treatment of the subject.
* Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
* Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.
* Subject has any condition which makes the subject unsuitable for study participation.

Primary outcomes:
measure: Phase 1 Part: Maximum Tolerated Dose (MTD) of Gilteritinib
timeFrame: Day 1 up to the end of Induction period cycle 1 (up to 42 days)
measure: Phase 1 Part: Recommended Expansion Dose (RED) of Gilteritinib
timeFrame: Day 1 up to the end of Induction period cycle 1 (up to 42 days)
measure: Phase 1 Part: Number of Participants With Dose Limiting Toxicities (DLTs) of Gilteritinib
timeFrame: Day 1 up to the end of Consolidation Cycle 1 (approximately up to 4 months)
measure: Phase 1 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
timeFrame: From the date of first dose up to 28 days after the last dose (approximately up to 2.6 years)
measure: Phase 2 Part: Complete Remission (CR) Rate: Induction Period
timeFrame: From the date of first dose up to the start of Consolidation (approximately up to 4 months)
Secondary outcomes:
measure: Phase 1 Part: Maximum Concentration (Cmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
measure: Phase 1 Part: Time to Attain Cmax (Tmax) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
measure: Phase 1 Part: Area Under Plasma Concentration-time Curve From Time 0 to 24 (AUC24) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
measure: Phase 1 Part: Area Under The Concentration-Time Curve From The Time Zero to The Last Measurable Concentration (AUClast) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 4 Consolidation period: Pre-dose, 1, 2, 4, 6, 10, and 24 hours post-dose on Cycle 1 Day 1
measure: Phase 1 Part: Plasma Trough Concentration (Ctrough) of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period: Pre-dose on Cycle 1 Day 8, 11, and 17 Consolidation period: Pre-dose on Cycle 1 Day 6 and 15
measure: Phase 1 Part: Plasma Trough Concentration of Cytarabine Concomitant With Gilteritinib With Induction and Consolidation Period
timeFrame: Induction period: Predose on Cycle 1 Day 1, 3, and 8 Consolidation period: Predose on Cycle 1 Day 2 and 6
measure: Phase 2 Part: Plasma Trough Concentration of Gilteritinib Concomitant With Induction and Consolidation Chemotherapy
timeFrame: Induction period : Predose on Cycle 1 Day 15 and 21 Consolidation period: Predose on Cycle 1 Day 8 and 15
measure: Phase 2 Part: Overall Survival (OS)
timeFrame: From the date of first dose up to the date of death (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Event Free Survival (EFS)
timeFrame: From the date of first dose up to the date of documented relapse, treatment failure or death from any cause (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Relapse Free Survival (RFS)
timeFrame: From the date of achievement of first CRc up to the date of documented relapse or death from any cause (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: CR Rate After Consolidation and Maintenance Period
timeFrame: From the date of first dose up to the end of each period (approximately up to 4.4 years)
measure: Phase 2 Part: CR Rate Without Minimal Residual Disease (MRD) After Each Treatment Therapy Period
timeFrame: From the date of first dose up to the end of each period (approximately up to 4.4 years)
measure: Phase 2 Part: CR With Partial Hematological Recovery (CRh) Rate After Each Treatment Therapy Period
timeFrame: From the date of first dose up to the end of each period (approximately up to 4.4 years)
measure: Phase 2 Part: Composite CR (CRc) Rate After Each Treatment Therapy Period
timeFrame: From the date of first dose up to the end of each period (approximately up to 4.4 years)
measure: Phase 2 Part: CR/CRh Rate After Each Treatment Therapy Period
timeFrame: From the date of first dose up to the end of each period (approximately up to 4.4 years)
measure: Phase 2 Part: Duration of CR
timeFrame: From the date of achieving CR up to the date of documented relapse (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Duration of CR/CRh
timeFrame: From the date of achieving CR/CRh up to the date of documented relapse (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Duration of CRh
timeFrame: From the date of achieving CRh up to the date of documented relapse (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Duration of CRc
timeFrame: From the date of achieving CRc up to the date of documented relapse (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Duration of Response (DoR)
timeFrame: From the date of achieving CR, CRp, CRi/PR up to the date of documented relapse (maximum duration: approximately 4.4 years)
measure: Phase 2 Part: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
timeFrame: From the date of first dose up to 30 days after the last dose (approximately up to 4.4 years)
Other outcomes:
Locations:
city: Anjo
country: Japan
facility: Site JP81037
state: Aichi
city: Nagoya
country: Japan
facility: Site JP00003
state: Aichi
city: Nagoya
country: Japan
facility: Site JP81003
state: Aichi
city: Nagoya
country: Japan
facility: Site JP81027
state: Aichi
city: Toyohashi
country: Japan
facility: Site JP81038
state: Aichi
city: Narita
country: Japan
facility: Site JP81010
state: Chiba
city: Matsuyama
country: Japan
facility: Site JP81039
state: Ehime
city: Yoshida-gun
country: Japan
facility: Site JP81007
state: Fukui
city: Maebashi
country: Japan
facility: Site JP00002
state: Gunma
city: Maebashi
country: Japan
facility: Site JP81001
state: Gunma
city: Fukuyama
country: Japan
facility: Site JP81026
state: Hiroshima
city: Otake
country: Japan
facility: Site JP81018
state: Hiroshima
city: Sapporo
country: Japan
facility: Site JP81014
state: Hokkaido
city: Sapporo
country: Japan
facility: Site JP81015
state: Hokkaido
city: Himeji
country: Japan
facility: Site JP81043
state: Hyogo
city: Kobe
country: Japan
facility: Site JP00007
state: Hyogo
city: Kobe
country: Japan
facility: Site JP81006
state: Hyogo
city: Mito
country: Japan
facility: Site JP81036
state: Ibaraki
city: Tsukuba
country: Japan
facility: Site JP81023
state: Ibaraki
city: Kanazawa
country: Japan
facility: Site JP81020
state: Ishikawa
city: Isehara
country: Japan
facility: Site JP81013
state: Kanagawa
city: Yokohama
country: Japan
facility: Site JP00006
state: Kanagawa
city: Yokohama
country: Japan
facility: Site JP81005
state: Kanagawa
city: Yokohama
country: Japan
facility: Site JP81024
state: Kanagawa
city: Sendai
country: Japan
facility: Site JP81035
state: Miyagi
city: Omura
country: Japan
facility: SIte JP81011
state: Nagasaki
city: Tenri
country: Japan
facility: Site JP81041
state: Nara
city: Shimono
country: Japan
facility: Site JP81022
state: Tochigi
city: Bunkyo-ku
country: Japan
facility: Site JP81040
state: Tokyo
city: Shinagawa-ku
country: Japan
facility: Site JP00005
state: Tokyo
city: Shinagawa-ku
country: Japan
facility: Site JP81032
state: Tokyo
city: Akita
country: Japan
facility: Site JP81029
city: Chiba
country: Japan
facility: Site JP81008
city: Fukuoka
country: Japan
facility: Site JP00001
city: Fukuoka
country: Japan
facility: Site JP81004
city: Fukuoka
country: Japan
facility: Site JP81025
city: Fukushima
country: Japan
facility: Site JP81031
city: Gifu
country: Japan
facility: Site JP81030
city: Kochi
country: Japan
facility: Site JP81033
city: Kumamoto
country: Japan
facility: Site JP81028
city: Kyoto
country: Japan
facility: Site JP81016
city: Nagasaki
country: Japan
facility: Site JP81012
city: Okayama
country: Japan
facility: Site JP81009
city: Osaka
country: Japan
facility: Site JP81019
city: Osaka
country: Japan
facility: Site JP81021
city: Busan
country: Korea, Republic of
facility: Site KR82005
city: Incheon
country: Korea, Republic of
facility: Site KR82002
city: Seoul
country: Korea, Republic of
facility: Site KR82001
city: Seoul
country: Korea, Republic of
facility: Site KR82003
city: Seoul
country: Korea, Republic of
facility: Site KR82004
city: Seoul
country: Korea, Republic of
facility: Site KR82006
city: Kaohsiung
country: Taiwan
facility: Site TW88604
city: Taichung
country: Taiwan
facility: Site TW88602
city: Tainan
country: Taiwan
facility: Site TW88601
city: Taoyuan
country: Taiwan
facility: Site TW88603
Study officials:
affiliation: Astellas Pharma Inc
name: Medical Director
role: STUDY_DIRECTOR
References: